TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics


TransCode Therapeutics, Inc., (RNAZ): $0.75

-0.16 (-17.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RNAZ to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RNAZ Stock Price Chart Interactive Chart >

Price chart for RNAZ

RNAZ Price/Volume Stats

Current price $0.75 52-week high $3.08
Prev. close $0.91 52-week low $0.28
Day low $0.71 Volume 5,984,903
Day high $0.94 Avg. volume 724,610
50-day MA $0.56 Dividend yield N/A
200-day MA $1.24 Market Cap 9.74M

TransCode Therapeutics, Inc., (RNAZ) Company Bio


TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.


RNAZ Latest News Stream


Event/Time News Detail
Loading, please wait...

RNAZ Latest Social Stream


Loading social stream, please wait...

View Full RNAZ Social Stream

Latest RNAZ News From Around the Web

Below are the latest news stories about TRANSCODE THERAPEUTICS INC that investors may wish to consider to help them evaluate RNAZ as an investment opportunity.

How should investors view TransCode Therapeutics Inc. Common Stock (RNAZ)?

TransCode Therapeutics Inc. Common Stock (NASDAQ:RNAZ) marked $0.67 per share on Friday, up from a previous closing price of $0.57. While TransCode Therapeutics Inc. Common Stock has overperformed by 18.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RNAZ fell by -72.30%, with highs and lows […]

US Post News | January 3, 2023

FDA Authorizes TransCode''s First-In-Human Clinical Trial With Solid Tumor Patients

TransCode Therapeutics Inc (NASDAQ: RNAZ ) has received written authorization from the FDA to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode''s lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, … Full story available on Benzinga.com

Benzinga | December 29, 2022

TransCode Therapeutics Inc. (RNAZ) produces promising results

As of Wednesday, TransCode Therapeutics Inc.’s (NASDAQ:RNAZ) stock closed at $0.61, up from $0.40 the previous day. While TransCode Therapeutics Inc. has overperformed by 51.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RNAZ fell by -75.60%, with highs and lows ranging from $3.13 to $0.28, […]

US Post News | December 29, 2022

TransCode stock surges ~25% on FDA nod to start phase 0 trial of cancer drug

TransCode Therapeutics (RNAZ) said it received authorization from the U.S

Seeking Alpha | December 29, 2022

FDA Authorizes TransCode's First-In-Human Clinical Trial With Solid Tumor Patients

TransCode Therapeutics Inc (NASDAQ: RNAZ) has received written authorization from the FDA to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in several advanced solid tumors. Related: TransCode Therapeutics Shares Sho

Yahoo | December 29, 2022

Read More 'RNAZ' Stories Here

RNAZ Price Returns

1-mo 11.44%
3-mo 24.98%
6-mo -43.18%
1-year -67.39%
3-year N/A
5-year N/A
YTD 11.44%
2022 -73.50%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7049 seconds.